Maegim한국어

프레스티지바이오로직

334970KOSDAQSector: Pharma & Biotech
₩1,784 0.00%Market cap ₩138.7BAs of Jul 21, 2026 close · updated once daily
C
Grade C39.8 ptsTop 71% of 2,523 stocks
Financial strength
20.2
Growth momentum
73.8
Price attractiveness
37.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

20.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
99.9%
Below median · Top 75.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
39.9%
Below median · Top 95.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-268.7%
Below median · Top 82.9% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-20.3%
Below median · Top 65.7% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

73.8
How much did revenue grow in a year?
Revenue growth (YoY)
477.8%
Above median · Top 2.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
830.3%
Above median · Top 0.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-0.8%
Below median · Top 55.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
8.1%
Above median · Top 47% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

37.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 82.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.03x
Above median · Top 42.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15